ERBB2 and neoplasm: MFLI-FRET in vivo imaging proved that the quantification of TZM–HER2 engagement in AU565 tumor xenografts is feasible, offering a high fluorescence lifetime signal-to-noise ratio in the tumors and acceptable FRET levels in animals injected with A:D = 2:1 ratios, but not in that injected with donor only.